Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease.

Ethgen M, Boutron I, Baron G, Giraudeau B, Sibilia J, Ravaud P.

Ann Intern Med. 2005 Jul 5;143(1):20-5.

PMID:
15998751
[PubMed - indexed for MEDLINE]
2.

Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.

Ethgen M, Boutron I, Steg PG, Roy C, Ravaud P.

Trials. 2009 May 4;10:29. doi: 10.1186/1745-6215-10-29. Review.

PMID:
19413903
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Reporting of harm in randomized controlled trials published in the urological literature.

Breau RH, Gaboury I, Scales CD Jr, Fesperman SF, Watterson JD, Dahm P.

J Urol. 2010 May;183(5):1693-7. doi: 10.1016/j.juro.2010.01.030. Epub 2010 Mar 17. Review.

PMID:
20299044
[PubMed - indexed for MEDLINE]
4.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
[PubMed - indexed for MEDLINE]
Free Article
5.

Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis.

Baron G, Boutron I, Giraudeau B, Ravaud P.

Ann Rheum Dis. 2007 May;66(5):651-7. Epub 2006 Dec 11. Review.

PMID:
17158823
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Published randomized controlled trials of drug therapy for dementia often lack complete data on harm.

Lee PE, Fischer HD, Rochon PA, Gill SS, Herrmann N, Bell CM, Sykora K, Anderson GM.

J Clin Epidemiol. 2008 Nov;61(11):1152-60. doi: 10.1016/j.jclinepi.2007.09.012. Epub 2008 Jul 10. Review.

PMID:
18619812
[PubMed - indexed for MEDLINE]
7.

Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Thabane L.

Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Review.

PMID:
16278497
[PubMed - indexed for MEDLINE]
Free Article
8.

Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials.

Cipriani A, Pretty H, Hawton K, Geddes JR.

Am J Psychiatry. 2005 Oct;162(10):1805-19. Review.

PMID:
16199826
[PubMed - indexed for MEDLINE]
9.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
[PubMed - indexed for MEDLINE]
10.

Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments.

Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group.

Ann Intern Med. 2008 Feb 19;148(4):W60-6.

PMID:
18283201
[PubMed - indexed for MEDLINE]
11.

Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs.

Brandt KD, Mazzuca SA.

Arthritis Rheum. 2005 Nov;52(11):3349-59. Review. No abstract available.

PMID:
16258927
[PubMed - indexed for MEDLINE]
Free Article
12.

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group.

CNS Drugs. 2008;22(7):587-602. Review.

PMID:
18547127
[PubMed - indexed for MEDLINE]
13.

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN.

Ann Intern Med. 2008 Jan 15;148(2):124-34. Epub 2007 Nov 19. Review.

PMID:
18025440
[PubMed - indexed for MEDLINE]
14.

Primer: assessing the efficacy and safety of nonpharmacologic treatments for chronic rheumatic diseases.

Ravaud P, Boutron I.

Nat Clin Pract Rheumatol. 2006 Jun;2(6):313-9. Review.

PMID:
16932710
[PubMed - indexed for MEDLINE]
15.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
[PubMed - indexed for MEDLINE]
16.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
[PubMed - indexed for MEDLINE]
17.

Reporting methods of blinding in randomized trials assessing nonpharmacological treatments.

Boutron I, Guittet L, Estellat C, Moher D, Hróbjartsson A, Ravaud P.

PLoS Med. 2007 Feb;4(2):e61. Review.

PMID:
17311468
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.

Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M; OMERACT-OARSI.

J Rheumatol. 2003 Jul;30(7):1648-54. Review.

PMID:
12858473
[PubMed - indexed for MEDLINE]
19.

Why choose hip osteoarthritis as a human model for evaluation of drugs in osteoarthritis?

Dougados M.

J Rheumatol. 2005 Jun;32(6):1154-6. Review. No abstract available.

PMID:
15977354
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk